[Etanercept in patients with juvenile idiopathic arthritis: systematic review and economic evaluation]

Brodszky V, Pentek M, Majer I, Karpati K, Gulacsi L
Record ID 32007000034
Hungarian, English
Authors' results and conclusions: Etanercept is an effective treatment for JIA compared to placebo in terms of improving symptoms. Incremental QALY gain per patients is 0,72 QALY. Etanercept is the only agent in this indication approved by FDA and EMEA so far.
Authors' recommendations: Etanercept can improve the symptoms of JIA: Scientific evidence suggests that etanercept can improve the symptoms of 74% of the patients. Health status and disease activity improved over a four year period, as the international and Hungarian database suggests. Etanercept treatment is the dominant strategy in JIA patients with an inadequate response or an intolerance to MTX Further study and surveillance are warranted. Outcome and harm from therapy and disease, based on scientific evidence identified, was not measured beyond four year. Funders should consider the value of prospectively measuring the costs and impact of therapy on the general JIA population.
Project Status: Completed
Year Published: 2006
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Hungary
MeSH Terms
  • Anti-Inflammatory Agents
  • Costs and Cost Analysis
  • Arthritis
Organisation Name: Unit of Health Economics and Technology Assessment in Health Care
Contact Address: Unit of Health Economics and Technology Assessment in Health Care Department of Public Policy and Management Budapest University of Economic Studies 1125 Budapest Fovam ter 8 Budapest HUNGARY Tel: +36 1 218 8197 Fax: +36 1 218 1466
Contact Name: laszlo.gulacsi@uni-corvinus.hu
Contact Email: laszlo.gulacsi@uni-corvinus.hu
Copyright: Unit of Health Economics and Technology Assessment in Health Care (HUNHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.